Selcaxen (Selpercatinib) Capsules
13191โด
14071โด
-6%
Selcaxen 40 mg (Selpercatinib) is a kinase inhibitor specifically designed to target RET (rearranged during transfection) receptor tyrosine kinase.
Manufacturer: Everest Pharmaceuticals. Each pack contains 30 capsules. It blocks the abnormal signaling pathways caused by RET gene mutations or fusions, thereby inhibiting tumor growth.
Precision Medicine:
Before initiating treatment, the presence of a RET gene fusion or mutation must be confirmed via a validated test. It is highly effective for RET-driven cancers.
Indicated for the treatment of patients with RET-positive tumors:
- ๐น Non-Small Cell Lung Cancer (NSCLC): Metastatic RET fusion-positive NSCLC in adults.
- ๐น Thyroid Cancer: Advanced or metastatic RET-mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer in adults and pediatric patients (12 years and older).
Packaging: 40 mg capsules.
โ ๏ธ ADMINISTRATION PROTOCOL (Weight-based):
- Dosing: Based on body weight:
โ Less than 50 kg: 120 mg twice daily.
โ 50 kg or greater: 160 mg twice daily. - Frequency: Take orally twice daily, approximately 12 hours apart.
- Administration: Swallow whole. Do not crush or chew. Can be taken with or without food.
- Interaction: Avoid taking with proton pump inhibitors (PPIs) simultaneously if possible (follow doctor's instructions).
- Hypersensitivity to Selpercatinib.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- Severe hepatic impairment (requires dose modification).
Common adverse reactions include:
- ๐ฉธ Labs: Increased AST/ALT (liver enzymes), hyperglycemia, decreased leukocytes.
- ๐ Cardiovascular: Hypertension, QT interval prolongation.
- ๐ Physical: Dry mouth, diarrhea, fatigue, edema (swelling).
- Patients require regular monitoring of liver function and blood pressure.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!